REMS Cannot Save Abbott's Obesity Drug Meridia In Face Of Cardiovascular Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm withdraws sibutramine as FDA finds no patient group for which risk mitigation would result in sufficient benefit.